Loading...
Loading...
India's metformin imports from SOUTH AFRICA total $3.2K across 34 shipments from 6 foreign suppliers. ZYDUS HEALTHCARE SA (PTY) LTD. leads with $1.2K in import value; the top 5 suppliers together control 98.4% of this origin. Leading Indian buyers include ZYDUS LIFESCIENCES LIMITED. This corridor reflects India's pharmaceutical import demand for metformin β a diversified sourcing base with multiple active suppliers from SOUTH AFRICA.

ZYDUS HEALTHCARE SA (PTY) LTD. is the leading Metformin supplier from SOUTH AFRICA to India, with import value of $1.2K across 6 shipments. The top 5 suppliers β ZYDUS HEALTHCARE SA (PTY) LTD., PHARMA DYNAMICS PTY LTD, RBC PHARMACEUTICALS (PTY) LTD, CIPLA SOUTH AFRICA, DR REDDY'S LABORATORIES PTY LTD (S.A.) β collectively account for 98.4% of total import value from this origin.
Ranked by import value (USD) Β· Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ZYDUS HEALTHCARE SA (PTY) LTD. | $1.2K | 6 | 38.8% |
| 2 | PHARMA DYNAMICS PTY LTD | $833 | 2 | 26.2% |
| 3 | RBC PHARMACEUTICALS (PTY) LTD | $539 | 1 | 17.0% |
| 4 | CIPLA SOUTH AFRICA | $284 | 22 | 8.9% |
| 5 | DR REDDY'S LABORATORIES PTY LTD (S.A.) | $236 | 2 | 7.4% |
| 6 | Hetero Drugs South Africa PTY LIMITED | $49 | 1 | 1.6% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ZYDUS LIFESCIENCES LIMITED | $1.2K | 6 | 38.8% |
| 2 | LUPIN LTD | $833 | 2 | 26.2% |
| 3 | MSN LABORATORIES PRIVATE LIMITED |
SOUTH AFRICA β India trade corridor intelligence
The South Africa to India trade corridor is currently stable, with no significant port congestion reported at major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, or Mundra. Freight rates have remained consistent over the past year, and the exchange rate between the Indian Rupee (INR) and South African Rand (ZAR) has shown minimal fluctuation, facilitating predictable cost structures for importers.
India's self-reliance initiatives, including the Production Linked Incentive (PLI) scheme, aim to boost domestic manufacturing and reduce import dependency. While these policies encourage local production, they may impact the volume of finished formulation imports from South Africa, as domestic manufacturers are incentivized to increase output. However, the demand for specialized formulations not produced locally may continue to sustain imports.
India and South Africa maintain a robust trade relationship, with ongoing discussions to enhance pharmaceutical trade. Negotiations for a Free Trade Agreement (FTA) are underway, focusing on mutual recognition of Good Manufacturing Practices (GMP) and other trade facilitation measures. These efforts aim to streamline the import process and strengthen bilateral pharmaceutical trade.
| $539 |
| 1 |
| 17.0% |
| 4 | FUSION SCIENTIFIC LABORATORIES PRIVATE LIMITED | $284 | 22 | 8.9% |
| 5 | DR.REDDY'S LABORATORIES LTD | $236 | 2 | 7.4% |
| 6 | HETERO LABS LIMITED | $49 | 1 | 1.6% |
The landed cost for importing Metformin formulations from South Africa to India includes the following components:
These components collectively determine the per-unit landed cost for the imported formulations.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Metformin into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, approval under Rule 122E is necessary before importation. Applications for registration and import licenses must be submitted to the Drugs Controller General of India (DCGI) at CDSCO. The registration process involves submitting Form 40 or 41, along with the required documentation, and may take several months, depending on the completeness of the application and the nature of the drug. Specific requirements for Metformin formulations under HS Code 30049099 include detailed product information, manufacturing details, and evidence of compliance with Indian standards.
Imported Metformin formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, with each batch requiring a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the products. If a batch fails to meet the required standards, it may be rejected, destroyed, or re-exported, depending on the severity of the non-compliance.
Between 2024 and 2026, the CDSCO has implemented stricter regulations for imported medicines to prevent the sale of unapproved or illegal drugs in the Indian market. Import registration and licensing have become mandatory, with the requirement for both import registration and a license from CDSCO as per the Drugs and Cosmetics Act and Rules. Additionally, the Directorate General of Foreign Trade (DGFT) revised Standard Input Output Norms (SION) A-290 in December 2025, changing the Unit of Measurement (UOM) for Metformin HCL inputs from a ratio-based measure to an absolute quantity per unit of export product, effective immediately.
Market demand, customs duty structure, and competitive landscape Β· Import duty: 17.10%
India imports finished Metformin formulations to meet the growing demand for diabetes management, particularly for patented or branded formulations and specific dosage forms not produced domestically. The domestic capacity may not fully satisfy the diverse needs of the Indian market, leading to reliance on imports. The market size for Metformin formulations in India is substantial, with a significant portion of the population requiring these medications for effective diabetes control.
The import duty structure for Metformin formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%, totaling 17.10%. There are no additional duties such as the National Calamity Contingent Duty (NCCD) or Anti-Dumping Duty applicable to this product. The Social Welfare Surcharge (SWS) is 10%, and the Integrated Goods and Services Tax (IGST) is applicable as per the prevailing GST rates. Exemptions or concessional rates are not available for imports from South Africa.
India sources Metformin formulations from South Africa due to the availability of patented formulations, specialized dosage forms, and high-quality products that may not be produced domestically. South African manufacturers offer competitive advantages in terms of product innovation and compliance with international quality standards. Other suppliers include China, Germany, and the United States; however, South Africa's share in the Indian market is notable due to these factors.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Metformin formulations from South Africa due to the availability of patented formulations, specialized dosage forms, and high-quality products that may not be produced domestically. South African manufacturers offer competitive advantages in terms of product innovation and compliance with international quality standards.
Compared to other origins such as China, the European Union, and the United States, South Africa offers competitive pricing, high-quality products, and adherence to international regulatory standards. While other countries may offer lower prices, South Africa's unique advantage lies in its product quality and compliance with international standards, making it a preferred source for certain formulations.
Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or regulatory non-compliance. To mitigate these risks, importers should diversify their supplier base, monitor currency trends, stay updated on regulatory changes, and establish contingency plans for supply chain disruptions.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Metformin suppliers from SOUTH AFRICA to India include ZYDUS HEALTHCARE SA (PTY) LTD., PHARMA DYNAMICS PTY LTD, RBC PHARMACEUTICALS (PTY) LTD. The leading supplier is ZYDUS HEALTHCARE SA (PTY) LTD. with import value of $1.2K USD across 6 shipments. India imported Metformin worth $3.2K USD from SOUTH AFRICA in total across 34 shipments.
India imported Metformin worth $3.2K USD from SOUTH AFRICA across 34 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Metformin sourced from SOUTH AFRICA include ZYDUS LIFESCIENCES LIMITED, LUPIN LTD, MSN LABORATORIES PRIVATE LIMITED. The largest buyer is ZYDUS LIFESCIENCES LIMITED with $1.2K in imports across 6 shipments.
The total value of Metformin imports from SOUTH AFRICA to India is $3.2K USD, across 34 shipments and 6 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records β the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
34 Verified Shipments
6 suppliers, 6 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists